Breaking News
Home / Oncology (page 2)

Oncology

Roche Enters License and Collaboration Agreement with ImaginAb for its CD8 Imaging Agent

LOS ANGELES, July 9, 2019 /PRNewswire/ — ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of the agreement, Roche will use ImaginAb’s novel minibody CD8 T cell imaging agent in immuno-oncology clinical …

Read More »

Genmab Announces Positive Topline Results in the Phase 2 Study of Daratumumab in Transplant Eligible, Newly Diagnosed Multiple Myeloma Patients

Copenhagen, Denmark; July 8, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that topline data from the Phase II GRIFFIN (MMY2004) study of newly diagnosed patients with multiple myeloma eligible for high-dose chemotherapy and autologous stem cell transplantation (ASCT), who were treated with daratumumab in combination with lenalidomide, bortezomib, …

Read More »

Pierre Fabre and Array Announce Interim Analysis Results from Phase 3 Study of Encorafenib Triplet Treatment in BRAF-Mutant Colorectal Cancer

CASTRES, France–(BUSINESS WIRE)–Pierre Fabre today announced interim analysis results from the Phase 3 BEACON CRC trial evaluating the combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (encorafenib Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. …

Read More »

FDA Declines to Approve Daiichi Sankyo’s Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Tokyo and Basking Ridge, NJ – (June 21, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of quizartinib for the treatment of adults with relapsed/ refractory FLT3-ITD acute …

Read More »

Report Finds Nearly 5.4 Million Cancer Survivors Suffer from Chronic Pain

A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States. The report, appearing as a Research Letter in JAMA Oncology, finds one in six survivors (16%), representing about 2.5 million people in the U.S., reported suffering …

Read More »

Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Relapsed or Refractory Follicular Lymphoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines …

Read More »

Bayer’s Stivarga Becomes First Compound Used in Clinical Trial Platform to Investigate New Therapies for Brain Cancer

WHIPPANY, N.J., June 19, 2019 /PRNewswire/ — Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer.1 The opening …

Read More »

Gilead Enters $2.4 Billion Deal with Nurix for Development of Innovative Targeted Protein Degradation Drugs

FOSTER CITY, Calif. & SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients …

Read More »

FDA Approves Merck’s Keytruda as Monotherapy for Patients with Metastatic Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based …

Read More »

FDA Grants Fast Track Designation to Torque’s First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

CAMBRIDGE, Mass., June 18, 2019 /PRNewswire/ — Torque, a clinical-stage immuno-oncology company developing Deep-Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Torque’s first Deep-Primed™ T cell immunotherapy program, TRQ-1501 (Deep …

Read More »